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ELLAGIC ACID-MEDIATED CK2 INHIBITION, A NATURAL, 
MULTIFUNCTIONAL STRATEGY TO TRIGGER CERVICAL CANCER CELL 
DEATH IN VITRO AND IN VIVO  
HANAN F. MOHAMMAD 
 
ABSTRACT  
Targeting CK2 for cancer therapy has proven effective in inhibiting tumor growth in 
several histology’s. The main goal of this study was to acquire pre-clinical data on a 
naturally occurring CK2-inhibitor (ellagic acid) in support of a human clinical trial. In 
vitro analysis included testing the spectrum of ellagic acid anti-cancer activity, defining 
the mode of growth inhibition in cancer cells and its impact on biochemical and 
molecular pathways. In vivo studies included determination of ellagic acid inhibitory 
effect in animal tumor models and toxicity analysis. We found that CK2 inhibition 
mediated by ellagic acid, was effective in inhibiting the growth of a wide spectrum of 
human cancer cells. These include breast cancer (MCF-7), kidney cancer (ACHN), colon 
adenocarcinoma (SW480), glioblastoma (U87), prostate cancer (DU-145), melanoma 
(WM164) and HPV -positive (HeLa) and -negative (C33A) cervical carcinomas. We used 
HeLa and C33A cell lines to determine EA mechanisms of action and impact on 
oncogenic, proliferative, and apoptotic pathways. Since CK2 controls over 300 target 
proteins involved in major biochemical and molecular pathways, we found that ellagic 
acid treatment was able to inhibit HPV oncogene expression, interrupt oncogenic 
pathways and induce anti-proliferative and pro-apoptotic pathways in HeLa cells. In 
vi 
 
C33A cells, CK2 inhibition bypassed tumor suppressor p53 and pRb mutation and 
induced apoptosis by inhibition of anti-apoptotic proteins IAPs. Comparing HeLa and 
C33A cells response to ellagic acid treatment, C33A cells were more sensitive to ellagic 
acid treatment compared to HeLa. The expression of HPV oncogenes in HeLa cells could 
delay HeLa response to death stimuli exerted by CK2 inhibition. CK2 inhibition and 
subsequent IAPs repression is the common event occurring in HeLa and C33A cells. 
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CHAPTER I 
INTRODUCTION 
     Cancer has now become the leading cause of death worldwide. It’s a disease that’s 
characterized by irregular proliferation, inappropriate cell survival, decreased apoptosis 
(programmed cell death), immortalization, invasion of surrounding tissue and metastasis 
to other organs. Cancer is responsible for high morbidity and mortality rates worldwide, 
specifically in the United States. According to National Cancer Institute (NCI) 
Surveillance Epidemiology and End Results (SEER), the estimated number of men and 
women diagnosed with cancer of all sites is 1,529,560 of which 569,490 die in 2010 
statistics. Relating cancer immortality to perturbed proteins signal transduction and to 
subsequent uncontrolled cellular growth and tumor development have originated the 
concept of Signal Transduction Therapy (STT) in molecular medicine (1). Protein kinases 
are the regulators of cell signaling pathways controlling cellular growth, proliferation and 
apoptosis. The fact that some kinases abnormal activity can cause major diseases, in 
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addition to their ability to be readily inhibited by catalytic site-directed molecules, has 
resulted in kinases emerging as the drugable kinome that can be targeted for therapy of 
most human diseases. As a general rule in cancer therapy, an effective target for cancer 
treatment must have a biological function that is indispensible in the cell, its abnormal 
activity and dysregulation must be  related to the malfunction of the cell, and be specific 
to cancer cells compared to the normal one (2).  Based on growing evidence in cancer 
research, one can argue that protein kinase CK2, previously known as Casein Kinase II 
demonstrates these traits. Therefore, the emergence of CK2 as suitable target for cancer 
therapy is put forth in this work. 
1.1 CK2 Characteristics. 
     Protein Kinase CK2 is a serine/threonine kinase (3). It recognizes acidic sites 
generally specified by clusters of carboxylic acid and/or pre-phosphorylated side chains 
downstream from the Ser/Thr residues with the one at position n+3 determining the 
minimum consensus sequence S/T-X-X-D/E (3) (4). CK2 exists as a tetramer composed 
of two catalytic subunits α (42-44 kDa), and α` (38 kDa), which exists in heterogeneous 
or homogenous nature, and two regulatory subunits β (25 kDa) (3, 5). Even though, the 
catalytic subunits exhibit more than 90% sequence similarity, they are the product of 
different genes and each has very distinctive C-termini, which suggests functional 
specialization (4, 6). A natural property of CK2-α catalytic subunit is the ability to utilize 
both ATP and GTP as phosphate donors while β subunit confers stability and substrate 
specificity of the enzyme (4, 7). CK2 phosphorylates more than 300 proteins which 
accounts for 18-27% of the cellular phosphoproteome localized in various cellular 
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compartments (3, 8). Protein kinase CK2 targets are involved in essential signaling 
pathways controlling vital cellular mechanism such as cell cycle, apoptosis, DNA 
replication and gene expression (4).  
1.2 CK2 Is Indispensible.  
     CK2 is essential to cellular growth, proliferation and survival. Previous knockout 
study of CK2α in Saccharomyces Cerevisiae resulted in a drastic decrease in yeast 
viability (9). In mice models, disruption of CK2α lead to embryonic death with multiple 
defects found in heart and neural tube (10). In different studies, CK2β knockout mice 
proved to cause embryonic death as well, while CK2α’ knockouts produced sterile mice 
offspring (11, 12). Therefore, CK2 function in the cell has been established to be 
indispensible.   
1.3 CK2 in Cancer versus Normal Tissue. 
     Protein kinase CK2 is ubiquitously expressed in all cell types. However, CK2 
distribution and expression level differ from one cell type to another and discriminates 
between normal and malignant cells. This difference in expression and distribution 
correlates with cellular state of proliferation and growth. CK2 is over-expressed in tissues 
involved in organogenesis or normal highly proliferative cells as well as all types of 
cancer tissue (7, 13). Comparing CK2 activity within normal tissue, it was found to be 
higher in the testis, brain and liver whereas in kidney, spleen, skeletal muscle, cardiac 
muscle and adrenal gland is relatively lower (7). However, over-expression of CK2 in 
normal highly proliferative tissue is only transient and much lower compared to the 
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persistent  over-expression in cancer cells (13). CK2 localization pattern is distributed 
among almost all cellular compartments (as a holoenzyme or separate subunits) including 
cytoplasm, nucleus, plasma membrane, cytoskeleton components, and endoplasmic 
reticulum (7). CK2 subunits are expressed in different proportions and may shuffle 
between cellular compartments as a holoenzyme or individual subunits in accordance 
with the functional requirements of the cell. For example, CK2α becomes rich in the 
nucleus at the late G1 early S phase of the cell cycle and remains there for the rest of the 
cycle, which indicates a correlation between CK2 subunits localization and cellular 
function and activity. CK2 holoenzyme translocation was evident in normal cells while 
studies done on cancer cells models indicate the possibility of individual subunits 
migration between cellular compartments (14-17). The discrimination between normal 
and malignant cells was further illustrated in the subcellular localization of CK2 subunits. 
CK2 is diffused in all cellular compartments in normal cells however, in cancer cells, 
CK2 is mainly localized in the nucleus
 
(13). 
1.4 CK2 Dysregulation Is Tightly Related To Tumorogenesis. 
     Several convincing evidences have implicated CK2 in the tumorigenesis and 
transformation of almost all cancer types. CK2 was found to be overexpressed and its 
catalytic activity elevated in several malignancies (1, 18). CK2 can desensitize cells to 
vital cellular checkpoints and elimination mechanism such as programmed cell death 
(apoptosis). CK2 promotes cellular growth and proliferation through the regulation of 
vital pro-survival signal transduction pathways such as NF-κB, Wnt, and P13K signaling 
(18, 19). Identifying the different signaling pathways that CK2 can perturb is 
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fundamental to understanding the mechanism of action of CK2 in promoting 
transformation and tumorogenesis. 
1.4.1 NF-κB Signaling Pathway. 
     Dysregulated activity of the transcription factor NF-κB was implicated in multiple 
malignances. NF-κB promotes the activation of anti-apoptotic proteins including BcL-xl 
and cIAPs, and cell cycle regulator cyclin D1. The inhibitor of κB (IκB) directly interacts 
with NF-κB to inactivate it and to hold it in the cytoplasm of most cells. Activation of 
NF-κB requires the proteosome dependent degradation of IκB. This degradation was 
found to be enhanced by CK2-mediated increase of IKK kinases expression or direct 
phosphorylation of IκB. Either pathway will activate proteosome-mediated destruction of 
IκB (20). As a result NF-κB is activated to translocate to the nucleus and induce 
transcriptional activation of anti-apoptotic proteins and cell cycle regulators, ultimately 
inducing uncontrolled cellular growth and inhibiting apoptosis.  
1.4.2 Wnt Signaling Pathway. 
     Wnt pathway is known as a key player in cancer development specifically in 
mammary gland and colorectal cancer (21, 22). It regulates cell proliferation, polarity and 
adhesion by keeping a sufficient level of β-catenin, a cofactor of transcription factor 
(TCF/LEF) family.  β-catenin is necessary for transcription activation of c-myc, cyclin D 
and a member of the inhibitor of apoptosis protein family (IAP) Survivin (19). Wnt is an 
extracellular protein which targets β-catenin for degradation. This destruction is inhibited 
by stabilizing protein dishevelled (Dvl). In this pathway, CK2 come into play by  
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Figure 1.1 Schematic presentation of CK2 implication in carcinogenesis through 
regulation of NF-κB, Wnt and P13K oncogenic pathways. (Figure from: Pinna et al. 
2010.) 
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phosphorylating Dvl, β-catenin and the complex β-catenin/Tcf/Lef. This phosphorylation 
activity promotes stabilization of targeted proteins and leads to increased β-catenin-
mediated transcription activation of multiple pro-survival and anti-apoptotic genes 
including Survivin (19, 23, 24).  
1.4.3 P13K/Akt Signaling Pathway: 
     The pro-survival/anti-apoptotic signaling pathway induced by P13 kinase (P13K) 
targets protein kinase B (PKB) or Akt that induces survival through direct inhibition of 
caspase 9, and pro-apoptotic protein BAD. This pathway is regulated by tumor 
suppressor PTEN (phophatase and tensin homolog deleted on chromosome 10). Removal 
of PTEN renders P13K-mediated Akt induction constitutively active (18). CK2 intervene 
at two sites in this transduction pathway. First CK2 targets PTEN for degradation by the 
proteasome (25). Second, CK2 directly phosphorylate Akt and promote its activation to 
further induce cell survival (26, 27). Overall, CK2 over-expression and dysregulated 
activity perturbs significant pro-survival and anti-apoptotic signaling pathways leading to 
cell transformation and tumorogenesis.  
1.5 CK2 A Key Suppressor of Apoptosis. 
     In addition, recent studies have shown that CK2 plays a key role in apoptosis 
suppression. Apoptosis is initiated via two pathways: the intrinsic and extrinsic pathways. 
Intrinsic apoptosis is initiated when pro-apoptotic Bcl2 family of proteins stimulates the 
mitochondrial release of a potent pro-apoptotic cytochrome c protein into the cytosol. 
This event initiates the activation of pro-caspase 9 and pro-caspase 3 which in turn  
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Figure 1.2 Apoptosis Pathways: Apoptosis cascade is initiated by extrinsic or intrinsic 
pathways, which can combine and lead to common execution of caspase cascade that 
result in DNA degradation and cell death. 
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 cleaves poly (ADP) ribose polymerase (PARP) and cause DNA damage and cell death 
(28-30). The extrinsic pathway is triggered by the interaction of tumor necrosis factor 
(TNF) receptors superfamily which includes Fas, TNFR1, DR4 and DR5 to their 
corresponding ligand FasL, TNF, and TNF-related apoptosis-inducing ligand (TRAIL). 
Death receptors are transmembrane proteins that, upon activation, oligomerize forming 
death inducing signaling complex (DISC) which subsequently activate pro-caspase8. 
Active caspase 8 can directly cleave pro-caspase 3 (28, 30). Caspase 8 can cross talk with 
intrinsic pathway through the cleavage of Bid (pro death member of Bcl2 family) and 
formation of truncated-Bid (tBid). tBid stimulates mitochondrial release of pro-apoptotic 
protein cytochrome c and induces subsequent caspase activation (28, 30). 
     Protein kinase CK2 was found to block cell response to death stimuli at multiple 
levels in the apoptotic cascade. CK2 phosphorylates Bid at serine and threonine residues 
located in caspase-8 recognition site which inhibits caspase-8 induced tBid formation 
(31-34). In addition, CK2 activates ARC (apoptosis repressor with caspase recruitment 
domain) to inhibit caspase-8 and block apoptosis cascade (35). Also, the implication of 
CK2 in NF-kB, Wnt and P13K pathways increases IAPs expression which inhibits 
caspase activity and block apoptosis. 
1.6. CK2 Enhances The Activity of Oncogenes. 
     CK2 was found to be upregulated and over-expressed in almost all malignancies. 
Dysregulation of CK2 kinase activity was found to enhance the oncogenic ability of some 
genes and lead to malignant transformation of tissue. For example, transfected animals 
with the catalytic subunit of CK2 in addition to c-myc or Tal-1 oncogenes enhanced 
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tumor phenotype specifically in leukemia and lymphoma models (3, 21, 36). Similar 
results observed in mammary gland models where over-expression of CK2α and MMTV 
enhanced breast cancer phenotype (10, 21). In addition, CK2 enhances oncogenic activity 
of Human Papilloma virus (HPV) oncogene E7. CK2 phosphorylates E7 at CR2 domain 
that contains the binding site of Rb proteins. This phosphorylation was found to enhance 
transformed phenotype by removing constraints on S-phase progression (37). 
Investigators have reported CK2α to behave as an oncogene. CK2α nuclear localization 
reflects the state of aggressiveness of prostate cancer as well as its role as a prognostic 
marker in squamous cell carcinoma of the lung (38, 39). In conclusion, CK2 over-
expression and dysregualtion is tightly related to the transformation and tumorogenesis of 
almost all cancer types. 
1.7 Targeting CK2 Activity to Treat Cancer. 
     Taking together the fact that CK2 is involved in several essential cellular pathways, 
and implicated in tumorogenesis and transformation of tissue have set mounting evidence 
to propose CK2 as a promising target for cancer therapy. Fortunately, protein kinases can 
be shut down using small molecules targeting their ATP binding site. There is a growing 
list of small ATP-site directed molecules that can be used to inhibit CK2 kinase activity. 
Each compound displays a different selectivity and specificity towards CK2 (Table 1). 
With growing interest in naturally occurring compounds therapy, Ellagic Acid (EA) with 
its high selectivity and specificity towards CK2 displays the most efficient molecule for 
CK2 inhibition. 
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1.8 CK2 Inhibitor: Ellagic Acid     
      Ellagic acid (4,4’,5,5’,6,6’ hexahydroxydiphenic acid 2,6,2’,6’-dilactone) is a 
naturally occurring,  relatively stable, polyphenolic compound that is found in raspberries 
(1500 μg/g dry weight), strawberries (630 μg/g) , cranberries (120 μg/g), and walnuts 
(590 μg/g) (40, 41). Ellagic acid has high selectivity and specificity towards CK2 with 
IC50 = 0.04 μM and Ki= 20 nM indicating the highest affinity to CK2 compared to other 
inhibitors (3, 18). Ellagic acid displays a unique binding mode in which it binds 
simultaneously to the phosphate binding region in the ATP binding pocket, and the hinge 
region through hydrogen bonding (42).EA also forms hydrophobic interactions with 
several CK2 residues that further stabilizes the EA-CK2 complex (43).  It is soluble in 
dimethyl sulfoxide (DMSO), ethanol, and polyethylene glycol (PEG400). Ellagic acid 
demonstrates higher solubility in PEG400 (8.3mg/ml) compared to ethanol (0.21 mg/ml) 
and DMSO (2.5mg/ml), thus PEG400 provides the highest drug concentration with 
minimal toxicity (41).  
1.9 Ellagic Acid Anti-Cancer Activity 
     Ellagic acid was reported to have in vitro anti-cancer activity and in vivo anti-tumor 
activity in several types of cancer (44, 45). In vitro studies reported that ellagic acid 
induces cell cycle arrest and apoptosis in human cervical cancer CaSki cells, colon 
carcinoma, and bladder cancer (46-48). It had also been reported that ellagic acid induces 
apoptosis through inhibition of NF-κB in pancreatic cancer MIA PaCa-2 and PANC-1 
cells (49). Moreover, animal studies demonstrated that ellagic acid has chemopreventive 
activity against chemically induced cancers of the skin, esophagus, lung and liver (50-
12 
 
54). However, the impact of ellagic acid on cellular biochemical and molecular pathways, 
and its therapeutic potential in animal models remain unclear. Herein we report a pre-
clinical study that investigates ellagic acid spectrum of anti-cancer activity, its impact on 
oncogenic and apoptotic pathways, and its therapeutic potential and tissue toxicity in 
animal models. Identifying ellagic acid mechanism of action could promote it for cancer 
therapeutics clinical trials.  
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CHAPTER II 
EFFECT OF POLYETHYLENE GLYCOL 400 (PEG400) ON ELLAGIC ACID 
ANTI-CANCER ACTIVITY 
 
2.1 Abstract: 
     In vitro ellagic acid cytotoxicity studies were mostly performed using dimethyl 
sulfoxide (DMSO) as a solvent.  Even though these studies have showed no cytotoxicity 
effect from DMSO by itself on cells screened, DMSO is known to be harsh solvent that 
can induce cell toxicity if used at concentrations > 1%. In this study, polyethylene glycol 
400 (PEG400) was used as ellagic acid vehicle. The efficacy in tumor inhibition was 
compared between PEG400- and DMSO-dissolved ellagic acid treatments. This was 
accomplished using in vitro anti-proliferative assay to screen a panel of 7 cancer cell lines 
of different histology including: brain carcinoma cell line U87, HPV positive and HPV 
negative cervical cancers Hela and C33 cell lines respectively, Breast adenocarcinoma 
MCF7, Melanoma WM167, colon cancer SW480 cell line, and ACHN kidney cancer. 
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They all showed sensitivity to increasing micromolar concentration of EA/PEG400 and 
EA/DMSO at different exposure times. However, C33 and MCF7 cell lines showed 
chemosensitivity to DMSO treatment. PEG400 showed less toxicity and no interference 
with EA anti-cancer activity. When cervical cancer cell lines response to EA treatment 
was compared at the same exposure time, C33 showed two fold increase in sensitivity 
compared to HeLa.  
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2.2 Introduction:  
     Polyethylene Glycol (PEG) is a long chain polymer made of ethylene glycol subunits. 
PEG400 is a member in the PEGs family with a molecular weight of 400. PEGs have 
multiple applications in pharmaceutical industry as drug delivery vehicle such as 
ointment, capsules, and suppositories makeup (1).  At higher molecular weight 
polyethylene glycol by itself can be used for constipation treatment, bowel cleansing and 
as an ingredient in artificial tear eye drops (1, 2). Also, PEG400 was determined to be 
widely used in the bases of cosmetics and skin creams (1).  The wide use of PEG400 
implies the safety and minimal cytotoxicity that can be induced if used as solvent for 
drug delivery. In addition, ellagic acid solubility studies have determined PEG400 to 
have higher efficiency in dissolving ellagic acid (solubility = 8.3mg/ml) compared to 
ethanol (0.21 mg/ml) and DMSO (2.5mg/ml) (3), therefore, providing higher 
concentration of drug and less solvent.  
     This study was designed to evaluate PEG400 as a safe and efficient vehicle that would 
not interfere with EA cancer inhibition effect, and to determine the spectrum of EA anti-
cancer activity. During phase I of the study, growth-based cytotoxicity assay was used to 
survey a panel of 7 aggressive human cancer-cell lines of different histology against 
PEG400-EA and DMSO-EA treatments at different exposure times ranging from 96-144 
hr. The panel screened includes colon adenocarcinoma (SW480), kidney carcinoma 
(ACHN), melanoma (WM164), brain cancer (U87), breast carcinoma (MCF7), HPV 
positive and HPV negative cervical carcinomas HeLa and C33.  The results from this 
survey led to phase II of the study in which, a metabolism-based cytotoxicity assay was 
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used to compare the effect of PEG400-EA treatment on two cell lines of the same 
histology HeLa and C33 at the same exposure time of 96hr. 
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2.3 Experimental Procedures: 
Drugs and chemicals. 
     The present study used Ellagic Acid Dihydrate (lot#D00076152), molecular weight = 
338.2 provided by Calbiochem. Polyethylene Glycol (PEG) molecular weight 400 was 
purchased from Fisher Scientific lot# 062734, and Dimethyl Sulfoxide (DMSO) 
molecular weight = 78.13 was obtained from aMRESCO lot# 2890C058. 
Cell Culture. 
     All cancer cell lines surveyed were maintained in RPMI (Cellgro), supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin (Cellgro). Cells were incubated 
in a humidified atmosphere with 5% CO2 at 37⁰ C.  
Preparation of EA/PEG400 and EA/DMSO formulations.  
     In accordance with solubility studies of Ellagic acid, stock solution of EA/PEG400 
was made by dissolving 30 mg EA in 4 ml PEG400, Incubated in the dark at 37⁰ C water 
bath for 5 minutes or until solution became clear and homogenous.  EA/DMSO stock was 
made with 10 mg EA in 3 ml DMSO mixed and kept in the dark. Both solutions were 
filtered in 0.2 μm syringe filter. Solutions were kept at -20⁰ C after usage.  
SRB Antiproliferative Assay. 
     Growth inhibition effect of ellagic acid was assessed by Sulforhodamine-B (SRB) 
colorimetric assay (4). HeLa, C33, U87, MCF-7, WM164, SW480 and ACHN were 
plated in 2- 96 well-plates at concentration of 2000 cells/well. After 24 hours of 
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incubation, cells were fixed with cold 10%  trichloroacetic acid (TCA) in one plate (to 
determine growth baseline) and the other plate was treated with increasing concentration 
of ellagic acid dissolved in PEG400 in one trial and DMSO in another. Two controls 
were set for each cell line, one untreated and one treated with the vehicle only at a 
concentration equal to that in highest ellagic acid dose. Cells were allowed to grow for 
96-144 hours before test was stopped by aspirating the medium and fixing cells with 10% 
cold TCA for >1 hour. Fixed cells were then washed 3 times with water and dried. Fixed 
cells were then stained with 0.4% (w/v) SRB dye (Sigma), dissolved in 1% acetic acid for 
30 minutes at room temperature. Dye was then extracted in mild basic conditions using 
10 mM unbuffered Tris base solution PH 10.5 for 1 minute. The absorbance of dye 
released from cells was measured by microplalte reader at 570 nm. Optical density 
measurements (OD) of the SRB dye is linear with the number of cells fixed at the bottom 
of the 96-well plate.  
MTS viability assay. 
     Cytotoxic effect of ellagic acid was assessed using the MTS colorimetric assay. HeLa 
and C33 cervical cancer cell lines were plated in 96-well plates at concentration of 5x10
3
 
cells/well. After 24 h of incubation, cells were treated with increasing concentration of 
ellagic acid dissolved in PEG400 and control was treated with the vehicle (PEG400). 
Cells were allowed to grow for 96 h before a 20 μl MTS solution was added to the wells 
and incubated in the dark at 37⁰ C for 3 h. Optical density (OD) was read at 492 nm using 
a 1420 WALLAC counter. Optical density readings of the formazan product are linear 
with the number of viable/metabolically active cells.  
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Statistical analysis. 
     Data are expressed as mean ± SEM from at least 3 independent experiments. 
Statistical analysis was done using student t-test. P< 0.05 was considered statistically 
significant.  
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2.4 Results  
     During phase I of the study, cells were screened with PEG400, DMSO, and ellagic 
acid in doses dissolved in PEG400 parallel to DMSO dissolved treatments. Cytotoxicity 
of solvents-treated cells was compared to untreated control.  The statistical difference 
between untreated and solvent treated cells was calculated using t-test. Comparing 
PEG400-treated and untreated cells, t-test showed a P-value > 0.05. This indicates no 
significant difference; therefore, we concluded that PEG400 has no cytotoxic effect on all 
cancer cell lines surveyed. On the other hand, MCF7 and C33A cells treated with DMSO 
showed P-value < 0.05 compared to untreated control. Therefore, these cell lines were 
screened using ellagic acid dissolved in PEG400 only. Overall evaluation of PEG400 
versus DMSO revealed that there was no chemosensetivity induced by PEG400 on all 
carcinoma cell lines tested, while some cell lines showed sensitivity to DMSO. 
Therefore, PEG400 was determined a safer vehicle for ellagic acid administration 
compared to DMSO.  
     To investigate ellagic acid spectrum of anti-cancer activity, we screened different 
cancer cell lines using ellagic acid doses (6.125-50 μmol/l). Using SRB assay, we 
determined IC50 values of cancer cell lines surveyed. MCF-7 cell line demonstrated 
growth inhibition at 96 hours with IC50 = 20 μM, while WM164 had IC50 > 50 μM, 
SW480 IC50 = 20 μM, U87 and ACHN IC50 were < 6.25 μM , HeLa IC50 = 40 μM and 
C33A cells showed IC50  of 10 μM at 144 hr of exposure time. This data revealed potent 
anti-cancer activity by ellagic acid in several cancer types. 
 
30 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Baseline Untreated DMSO PEG400
O
D
 a
t 
5
7
0
 n
m
WM164
0
20
40
60
80
100
120
0 6.25 12.5 25 50
EA (uM)
W
M
1
6
4
 c
e
ll
 g
ro
w
th
 (
%
) EA in DMSO
EA in PEG400
0
20
40
60
80
100
120
0 6.25 12.5 25 50
EA (uM)
S
W
4
8
0
 c
e
ll
 g
ro
w
th
 (
%
)
EA in DMSO
EA in PEG400
*
**
0
0.1
0.2
0.3
0.4
0.5
0.6
Baseline Untreated DMSO PEG400
O
D
 a
t 
5
7
0
 n
m
SW480
*
**
 
 
Figure 2.1. Effect of EA/ DMSO vs. EA/PEG400 formulations on WM164 and                  
SW480 cell growth. A,C. WM164 and SW480 cells were treated with 6.25-50 μM 
EA/DMSO and EA/PEG400 for 120 h. Data represent the mean ± SEM of 8 different cell 
density readings. B, D.  *p > 0.05 for DMSO treated vs. untreated control group and                                                                                                                                                      
**p > 0.05 for PEG400 treated vs. untreated control.  
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Figure 2.2.  Effect of EA/DMSO vs. EA/PEG400 formulation on ACHN and U87 cell 
growth. A, C. ACHN and U87 cells were treated with 6.25-50 μM EA/DMSO and 
EA/PEG400 for 120 and 96 h respectively. Data represent the mean ± SEM of 8 different 
cell density readings. B, D. *p > 0.05 for DMSO vs. untreated control and ** p > 0.05 for 
PEG400 vs. untreated group for both cell lines. 
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Figure 2.3.  Effect of EA/DMSO vs. EA/PEG400 formulation on C33 and MCF-7 
cell growth. A, C. C33 and MCF-7 cells were treated with 6.25-50 μM EA/DMSO and 
EA/PEG400 for 144 and 96 h respectively. Data represent the mean ± SEM of 8 different 
cell density readings. B, D. *p < 0.05 for DMSO vs. untreated control and **p > 0.05 for 
PEG400 vs. untreated group for both cell lines. 
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Figure 2.4.  Effect of EA/DMSO vs. EA/PEG400 formulations on HeLa cell growth. 
A. HeLa cells were treated with 6.25-50 μM EA/DMSO and EA/PEG400 for 96 h. Data 
represents mean ± SEM of 8 different cell density readings. B. *p > 0.05 for DMSO vs. 
untreated control, and **p > 0.05 for PEG400 vs. the untreated group.  
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Figure 2.5. Comparison analysis of EA/PEG400 effect on HeLa vs. C33 cell lines. 
Cells were treated with 6.25-50 μM EA/PEG400 doses for 96 h. Data represents mean ± 
SEM of 2 independent MTS assays.  
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Cell Line IC50 (μM) 
MCF7 (Breast Cancer) 18 
WM164 (Melanoma) 50 
U87 (Brain Cancer) 4 
SW480 (Colon Adenocarcinoma) 18 
ACHN (Kidney Cancer) 4 
HeLa (HPV+Cervical Cancer) 45 
C33 (HPV-Cervical Cancer) 18.7 
 
Table 2.1. Determination of the EA IC50 values for each cell line screened.  
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2.5 Discussion 
     The potential use of ellagic acid for in vivo pharmaceutical treatment requires safe 
vehicle to deliver the drug. This initial study points out the potential of PEG400 as a 
particularly safe vehicle for ellagic acid delivery for in vivo studies or clinical trials.   
Testing the toxicity of the solvent PEG400 revealed no growth inhibition or viability 
reduction on all cell lines screened. Moreover, its use as a solvent for ellagic acid therapy 
did not compromise ellagic acid anti-cancer activity. However, for drug development and 
discovery, other factors like cellular uptake and metabolism, and its effect over long-term 
drug regimentation should be assessed in future studies.  
     As already mentioned in the results section, PEG400-ellagic acid was able to induce 
cancer cell growth inhibition at micromolar concentrations when screened against a panel 
of seven aggressive human malignancies. This anti-proliferative activity presented in this 
study reinforces the previously documented anti-cancer ability of ellagic acid in a wide 
range of cancer types. However, the novelty of this study is represented in the use of 
PEG400 for EA administration for maximal safety and efficiency.  
     It is noteworthy that the SRB assay used to assess ellagic acid inhibitory effect on 
different cancer cell lines from different tissues is used for large scale anti-cancer drug 
discovery program at the National Cancer Institute (NCI) (5, 6). However, this assay 
depends on the growth rate of cells. Therefore, exposure time differs from one cell line to 
another depending on how fast these cells grow and reach 70-80% confluence before the 
test can be terminated.  Therefore, to compare two cell line’s response to ellagic acid 
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treatment, exposure time has to be fixed which is not possible with SRB assay. The MTS 
reagent is metabolically reduced by mitochondria to formazan colored products (7, 8). It 
is a time sensitive method but it is not affected by growth rate thus exposure time can be 
controlled for comparison purposes. Upon comparison, cervical cancer cell lines HeLa 
and C33 responded differently to ellagic acid treatment at 96 hr. This difference in 
sensitivity raises the question of why HeLa responds differently to ellagic acid treatment 
compared to C33. We initially hypothesized that HPV oncogenic activity may delay 
HeLa response to EA-induced death stimuli. This suggests differences in the underlying 
mechanism of action of ellagic acid in HeLa and C33 cells. Therefore, HeLa and C33 are 
suitable models to study the role of EA-mediated CK2 inhibition in cancer cells. The 
upcoming studies are focused on identifying EA mechanism of action through the 
evaluation of the differences in CK2 inhibition, and its impact on HPV oncogenic 
activity, cell cycle progression, and apoptotic pathways. In vivo studies are also 
performed to validate EA suitable for a clinical trial. 
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CHAPTER III 
HPV-POSITIVE CERVICAL ADENOCARCINOMA:  
ELLAGIC ACID INHIBITS MULTIPLE ONCOGENIC PATHWAYS IN HELA 
CELL LINE IN VITRO AND EXERTS ANTI-TUMOR ACTIVITY IN VIVO.  
 
3.1 Abstract 
     Cervical cancer is the second most common malignancy among women worldwide.  
Herein, we report that ellagic acid (EA), a natural polyphenolic compound, exerts anti-
proliferative and pro-apoptotic activity in HPV18 (+) human cervical adenocarcinoma 
cells (HeLa) in a dose- and time-dependent manner.  Inhibition of casein kinase 2 (CK2) 
activity by ellagic acid resulted in abrogation of HPV oncogene E6 and E7 expression.  
The decrease in E6 expression correlated with stabilization of p53 and apoptosis 
induction. EA induced mitochondrial-mediated caspase activation via the release of 
cytochrome c into the cytosol and subsequent poly (ADP) ribose polymerase (PARP) 
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fragmentation and cell death. The decrease in E7 correlated with inhibition of cyclin A 
expression, and inhibition of cell cycle progression.  Finally, treatment of athymic-nude 
mice treated EA resulted in inhibition of cervical cancer xenograft growth and longer 
survival compared to non-treated mice, confirming the potent anti-tumor activity of EA.  
Our data strongly suggest that EA has anti-tumor activity which could make it suitable 
for the prevention of HPV induced cervical carcinoma. 
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3.2 Introduction:  
     Cervical cancer is the second most common malignancy among women worldwide 
with >80% of the cases occurring  in developing countries (1). The geographic 
distribution of cervical cancer is highest in Latin America, sub-Saharan Africa, south 
Asia and Southeast Asia (2). Indonesia, with a population of 200 million, has 79.14 
million women age 15 years and older who are considered to be at high risk of 
developing cervical cancer. According to World Health Organization (WHO) 2010 data, 
cervical cancer cases in Indonesia were estimated to be 13,762 with a mortality rate of 
7,493 women per year. Cervical cancer ranks as the second most prevalent cancer among 
women between 15 and 44 years of age in Indonesia (3). Human papilloma virus HPV16 
and 18 DNA was discovered in cervical malignancies by Harald zur Hausen (winner of 
the Nobel Prize in Medicine, 2008). High risk types HPV 16 and 18 account for almost 
50% of all female genital HPV infections, and they are present in 90% of human cervical 
carcinomas (4, 5). Therefore, HPV16 & 18 has been identified as the most prominent 
etiologic factor in cervical malignancy. According to WHO Information Center on HPV 
and Cervical Cancer, 80.1% of invasive cervical cancers in Indonesia are related to HPVs 
16 and 18.  
     Viral survival in host cells depends on disrupting normal cellular machinery, 
inhibiting cellular defense mechanisms and exploiting cell signaling pathways to 
stimulate viral DNA replication and the production of viral particles. Persistent HPV 
infection leads to viral DNA integration into the host genome. Oncogenesis results when 
cells escape normal constraints on cell survival and proliferation. Loss of cellular control 
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over HPV oncogene transcription activity leads to induction of viral oncogene E6 and E7 
expression (6). E6 removes normal constraints on cell survival while, E7 removes normal 
constraints on cell proliferation. Thus, elevated viral oncogene expression is essential to 
the transformation and immortalization of human cervical epithelial cells (7, 8).  
     High risk (HR) HPV E6 targets wild-type (wt) tumor suppressor protein p53 for 
ubiquitin-mediated degradation (7, 9). p53 plays an essential role in the host’s defensive 
mechanism against DNA damage. Tumor suppressor protein p53 can induce apoptosis in 
a transcription-dependent pathway by increasing expression of DR5 and FAS/APO1 
(membrane death receptors) and the pro-apoptotic Bcl2 family members (10-12). In 
addition, p53 exerts its tumor suppressive activity via a transcription-independent 
pathway involving p53 translocation to the mitochondria. At the mitochondria, p53 
causes oligomerization and activation of the pro-apoptotic Bcl2 proteins that increases 
mitochondrial outer membrane permeability for the pro-apoptotic protein cytochrome c to 
be released into the cytosol and activate the caspase cascade (4, 13). Oncoprotein E7 
causes dysregulation of the cell cycle by binding pRb, p107 and p130 (14, 15). HPV-E7 
specifically targets pRb at the E2F binding site. pRb-free-E2F are active transcriptional 
factors that induce gene expression of proteins controlling S-phase progression of the cell 
cycle such as cyclin E and cyclin A which leads to uncontrolled cell cycle progression 
and cell proliferation (16). Hence, HPV oncogenic activity mediates malignant 
transformation of epithelial tissue. 
     This study demonstrates the in vitro and in vivo effect of EA on HPV18-positive 
cervical cancer cells. The HeLa cell line expresses elevated levels of CK2 as well as 
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HPV18 oncoproteins E6 and E7; thus it represents a good model to study the role of EA-
mediated inhibition of CK2 activity on cell proliferation, survival, and HPV oncogene 
expression. 
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3.3 Experimental Procedures:  
Cell culture. 
     HeLa cells were maintained in RPMI (Cellgro), supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin (Cellgro). Cells were incubated in 5% CO2 at 37⁰ C.  
CK2 activity assay 
     CK2 activity in HeLa cells was measured using whole cell lysates. Cells were 
extracted using ice-cold hypotonic buffer containing 20 mM Tris buffer, pH 8.0, 10% 
glycerol, 0.05% nonidet-P40, 2.0 mM EDTA, 2.0 mM EGTA and a cocktail of protease 
and phophatase inhibitors. Cell suspension was kept on ice for 30 minutes, and then 
centrifuged at 10,000 xg for 10 minutes at 4⁰ C. Endogenous kinase activity of CK2 was 
measured by CKII assay Kit (Upstate Biotechnology/ Millipore). 1 μg protein of cell 
lysates was added to a total volume of 40 μl containing assay dilution buffer (20mM 
MOPS, pH7.2, 25mM β-glycerol phosphate, 5mM EGTA, 1mM sodium orthovanadate, 
and 1mM dithiothreitol), 0.4 mM of CK2-specific substrate peptide (R3D3SD3), inhibitor 
cocktail to block activity of other serine/threonine kinases in lysates, and diluted [γ-32P] 
ATP in MgCl2. The mixture was incubated at 30⁰C for 10 minutes, and then reaction was 
stopped by adding 20 μl of 40% trichloroacetic acid (TCA). Twenty-five microliter of 
reaction mixture was transferred to P81 paper discs and allowed to bind for 30 seconds. 
Paper discs were washed 3 times with 0.75% phosphoric acid for five minutes each and 
one time with acetone, allowed to dry before they were transferred to scintillation vials 
with 2 ml of scintillation cocktail. Radioactivity of CK2 was counted using scintillation 
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counter, expressed as c.p.m percentage of control radioactivity. Parallel to CK2 activity 
assay, CK2 expression level was analyzed by standard method for western blotting. 
Cell cycle analysis 
     HeLa cells were plated at density of 1 x 10
5
cell/well and incubated for 24h with 50 
μM EA. The cells were then harvested and fixed in 90% ethanol at 4⁰ C. Cells were then 
washed with PBS and resuspended in a solution containing propidium iodide, sodium 
citrate, triton X and RNase, and incubated at 37⁰ C in the dark. After 30 min of 
incubation, samples were analyzed by Cytomics FC500 flow cytometer (Beckman 
Coulter), Quantitative cell cycle analysis was performed using CXP software. 
Trypan Blue Assay. 
     Trypan blue dye exclusion assay was done to test cytotoxicity of cervical cancer cell 
lines to ellagic acid in time dependent manner. HeLa cells were treated with 50 μM 
ellagic acid for 24, 48, 72 and 96 h. At specified time points samples were trypsinized 
and harvested and an aliquot of 500 μl was counted using Beckman Coulter Vi-Cell XR 
cell viability counter. Results were then compared to control at (0 h) which was treated 
with Peg400 only and collected after 96 h of incubation time.  
SYBR Green-quantitative polymerase chain reaction (syber green-qPCR) detection. 
     Total RNA from treated cells was extracted using RNeasy mini kit (QIAGEN). cDNA 
was synthesized according to manufacturer’s protocol for reverse transcriptase (RT). 
Primers for HPV18-E6/E7 and β-actin were synthesized by Invitrogen. Sequence for  
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HPV18-E6 primer:  
5’-GGTGCCAGAAACCGTTGAATC-3’,  
3’-CGAATGGCACTGGCCTCTATAG-5’ 
HPV18-E7 primer: 
5’-CGAACCACAACGTCACACACAAT-3’ 
3’-TGCTGGAATGCTCGAAGGT-5’ 
β - Actin primer: 
5’-CCGAGGACTTTGATTGCACA-3’ 
3’-AGTGGGGTGGCTTTTAGGAT-5’ 
HPVLevels of m-RNA for HPV18 oncoproteins in treated HeLa cells were determined 
using SYBR green master mix (Clonetech) and Fast 9400 real time PCR system (Applied 
Biosystems). The qPCR reaction total final volume was 20 μl consisting of 10 μl SYBR 
green 2x master mix, 0.2 μl of forward and reverse primers (final concentration 0.2 
pmol/μl ) as well as 0.2 μl of ROX reference dye and 9.4 μl of H2O. Instrument was set 
for regular 2 hours qPCR running conditions. Instrument run started with holding stage at 
50⁰C for 20 seconds, and 96⁰C for 10 minutes. This was followed by 40 amplification 
cycles of 95⁰ C for 15 sec, 60⁰ C for 1 min and the melting curve to assess specificity of 
PCR product. The data were analyzed using comparative CT (∆∆CT) and target genes were 
quantified using the formula (2
∆∆CT) and normalized to an endogenous reference (β-actin) 
that served as loading control. Final analysis of target genes expression was compared to 
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control group (Time 0). Average gene expression values were then blotted in bar graph 
from n=6 for HPVE7 and n=3 for HPVE6. 
Oncoproteins E6 and E7, as well as their downstream targets (p53 and cyclin A) 
expression levels were evaluated by resolving 35 µg of total cell lysate using western 
blots and probing with HPV18-E6 and HPV18-E7 antibody (Abcam).  
Annexin-V assay/ flow cytometry. 
     HeLa cells were treated with 50 µM ellagic acid and Peg400 (control) and incubated 
at 37⁰C. Cells were trypsinized and harvested at 24, 48, 72 and 96 h, washed once with 
cold PBS and resuspended in 100 µl Annexin-V binding buffer at concentration of 1x10
3
 
cells /μl. According to the manufacturer’s protocol, cells were then incubated with FITC-
Annexin V and propidium iodide (PI) solution (FITC Annexin V Kit II, BD 
pharminogen) for 15 min at room temperature in the dark. Apoptosis induction was then 
analyzed on Cytomics FC500 flow cytometer (Beckman Coulter), using CXP software.  
Apoptosis array analysis.  
     HeLa cells were plated in 100 mm dishes at a density of 1x 10
5
 cells/ml. Cells were 
treated with 0 or 50 μM ellagic acid and incubated at 37⁰ C for 96 h. After trypsinizing 
and harvesting of cells, they were rinsed with PBS and extracted at 1x10^7 cells/ml in kit 
lysis buffer (Human Apoptosis Array Kit; R&D Systems). The lysates were resuspended 
and rocked gently at 4⁰ C for 30 min. After centrifuging at 14,000 x g for 5 min, the 
supernatant was transferred into a clean tube. 400 µg protein was incubated with 
apoptosis array membrane according to manufacturer’s protocol. Arrays were read by the 
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typhoon and quantitative analysis of protein levels was done using Image Quant TL 
v2005.  
Immunoblot. 
     Total cell lysate was prepared by lysing the cells in a buffer containing 150 mM 
sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulphate (SDS), and 50 mM Tris at pH 8.0 with a cocktail of protease inhibitors. Protein 
concentrations were determined using BCA protein assay (Biorad). An aliquot of 35 μg 
protein was taken from all samples and resolved on 12% polyacrylamide-SDS gel and 
transferred to PVDF membrane using semi dry transfer method. The membrane was 
blocked with 5% milk and incubated with anti-PARP antibody, anti-Caspase 3 (Cell 
Signaling). 
Cytochrome c release 
     HeLa cells treated with 50 μM ellagic acid for 0, 24, 48, and 72 hours were swelled 
using hypotonic solution containing (20 mM HEPES, pH 7.5, 10 mM KCL, 1.9 mM 
MgCl2, 1.0 mM EGTA and 1.0 mM EDTA, and a cocktail of protease inhibitors on ice 
for 30 minutes, then homogenized using dounce homogenizer. Cell lysate was 
centrifuged at 800 xg for 15 minutes at 4⁰ C to pellet nuclei and cellular debris. 
Supernatant was transferred to new microfuge tubes and spun down at 6000 xg for 15 
minutes at 4⁰ C to pellet mitochondria (17). Supernatant from second centrifugation were 
transferred to new microfuge tubes, protein was measured using BCA assay (Biorad), and 
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resolved on 12% polyacrylamide gel. Gel was then transferred on PVDF membrane, 
blocked with 5% milk and probed with anti-cytochrome c antibodies. 
Ellagic acid effect on HeLa xenograft.  
     Animal experiments were performed in accordance with guidelines approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Cleveland Clinic. Female 
athymic nu/nu mice were purchased from Case Comprehensive Cancer Center (CWRU). 
Cell inoculation was achieved by injecting mice subcutaneously with 1x10
6
 HeLa cells 
suspended at 1x10
7
 cells/ml. Mice were randomized into two groups and were monitored 
daily until tumors reached approximately 100 mm
3
 in volume. Control groups received 
vehicle (Peg400) given intratumorally (IT) in a volume of 25 μl. Second group received 
ellagic acid treatment intratumoral at concentration 8 mg/kg. Treatments were given three 
times a week, tumor dimensions were measured using calipers and volume of tumor was 
calculated using the formula (Volume = 4/3 π a2b, where a=minor radius and b=major 
radius of the tumor).  
Histology and immunohistochemistry.  
     Animals were euthanized and organs (liver, kidney, lungs, and spleen) along with 
tumors were harvested and fixed in 10% neutral buffered formalin. Sections of organs 
and tumors were stained with hematoxylin and eosin (H&E). Slides were viewed 
microscopically.  
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3.4 Results 
Ellagic acid inhibits CK2 kinase activity. 
     To confirm the inhibitory effect of ellagic acid on CK2 activity in HeLa cells, kinase 
activity was measured in the presence of a specific peptide substrate. A decrease in CK2 
kinase activity following EA treatment was at maximum at 72 h followed by a drug 
rebound effect evident at 96 h (Fig. 3.1A). CK2 expression was not decreased, at the 
contrary; there is an increase in CK2 expression after 72 h of ellagic acid treatment (Fig. 
3.1B)  
In vitro anti-proliferative and pro-apoptotic effect of EA.   
     To assess the effect of EA on cell cycle progression, flow cytometry was performed.  
Ellagic acid induced marked increase of S- phase from 15% to 32.3%, with a concomitant 
decrease in G0/G1 phase from 51.3% to 22.1% (Fig. 3.2). To test EA effect on viability of 
HeLa cells, cell count of trypan blue stained cells was performed. Treatment with fixed 
concentration of 50 μM EA resulted in inhibition of HeLa cells viability in time 
dependent manner. HeLa IC50 value was determined to be 45μM EA (Fig. 3.3)  
Inhibition of E6 and E7 expression level, and its effect on downstream target 
proteins. 
     Quantitative PCR analysis showed that EA caused a 40% reduction in the level of E6 
and E7 mRNA at 24 hours. The inhibition gradually increased to > 80%, reducing E6 and 
E7 mRNA to 20% of control (Fig. 3.4A). Similar reduction in protein expression was 
also seen with immunoblotting (Fig. 3.4B). To correlate the inhibition of E6 and E7 
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expression on their downstream protein targets, we tested the expression of p53 and E2F 
transcriptional target, cyclin A (Fig. 3.4C). Inhibition of E6 resulted in increased 
expression of p53 in HeLa cells, and cyclin A was reduced in expression following 
decreased E7. Overall, our data demonstrates that EA inhibits E6 and E7 expression, thus 
neutralizing their pathological effect on these critical downstream target proteins. 
Ellagic acid induces apoptosis. 
     In figure 3.5A, we measured apoptosis by Annexin V-FITC staining which detects 
phosphatidyle serine (PS) exposure in the outer leaflet of the plasma membrane. A fixed 
50 μM EA treatment caused a shift to FITC-annexinV-positive/PI-negative cells (early 
apoptosis) and FITC-annexinV-positive/PI-positive cells (late apoptosis). Figure 3.5B, a 
quantitative time- dependent analysis indicates a significant increase in the total number 
of apoptotic cells (early + late) with increased time of EA treatment.  
Ellagic acid targets activates apoptotic proteins in HeLa cells.  
     We next examined the effect of EA on various pro-apoptotic and anti-apoptotic 
components by fractionation, western blotting, and array analysis. Consistent with the 
observed apoptosis induction, we found that EA treatment induced caspase 8 cleavage, 
cytochrome c release into the cytosol and subsequent caspase-3 and PARP cleavage (Fig. 
3.6). Array analysis showed that incubation of HeLa cells with EA results in a dramatic 
decrease in expression in the IAP’s family of apoptosis inhibitors specifically cIAP-1, 
XIAP and survivin, and an increase in TRAIL R2/ DR5 death receptor (Fig. 3.7A, B). 
53 
 
This data implicates upregulation of pro-apoptotic proteins and downregulation of anti-
apoptotic proteins in the EA mechanism of action.  
In vivo anti tumor effect of ellagic acid. 
     Both intra-tumoral and intra-peritoneal administration of ellagic acid resulted in 
inhibited tumor growth in HeLa xenografts. All vehicle-treated mice exhibited 
progressive increase in HeLa tumor volume. HeLa tumors showed a 55% reduction in IT- 
treated tumors and 87% in IP (Fig. 3.8, 9). To further prove the effect of ellagic acid on 
cervical cancer tumors, we treated HeLa control animals with 8mg/kg ellagic acid 
intratumorally starting day 57. Treated tumors became black and necrotic. With H&E 
tissue analysis of control and treated tumor sections, treated tumor area appeared to be 
vacuolated containing cellular debris which is indicative of necrosis (Fig. 3.10). H&E 
staining of major organs revealed no tissue toxicity following EA treatment (Fig. 3.11). 
 
 
 
 
 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.  Ellagic acid inhibits endogenous CK2 phosphorylation activity. 
A.CK2 phosphorylation activity was drastically inhibited in hela cells treated with 50μM 
ellagic acid for 24, 48 and 72 hours. CK2 activity was calculated compared to control 
sample at time 0 and the mean of a triplicate run ± SE are shown. At 96h a drug rebound 
effect was evident. B. Immunoblot representing CK2 expression level with ellagic acid 
treatment and β-actin as an internal control. Immunoblots showing that ellagic acid 
inhibits CK2 kinase activity but does not decrease CK2 expression.   
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Figure 3.2.  Ellagic acid causes S-phase arrest in HeLa cells. 
Flow cytometry analysis of HeLa cells exposed to 50μM ellagic acid at indicated time 
points shows significant increase in cells accumulated in S-phase relative to control cells. 
Data shown are based on the mean of n=3 ±SE.  
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Figure 3.3. The effect of Ellagic acid treatment on HPV (+) cervical carcinoma viability.  
 A 50μM ellagic acid dose induced marked reduction in HeLa cells viability in time 
dependent manner. A single dose administration was effective up to 96 h   of incubation 
time. 
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Figure 3.4.  Ellagic acid inhibits HPV18 oncogenesE6 and E7 expression.  
A. Utilizing quantitative PCR analysis and based on 6 separate experiments, E6- and E7- 
mRNA levels were markedly decreased following a single dose of 50μM ellagic acid. E6- 
and E7- mRNA expression was compared to internal control (β-actin) and data presented 
in mean ± SE. B. Representative immunoblots of E6 and E7 protein expression showing a 
decrease in protein levels as well. C. Data present stabilization of p53 and decrease in 
cyclin-A protein level as a consequence of E6 and E7 inhibition. 
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Figure 3.5.  FITC Annexin V staining illustrates apoptosis induction. 
A. A density scattergram showing viable untreated (control) HeLa cells mostly 
concentrated in M3 (PI negative, FITC Annexin V negative). With increasing time of EA 
treatment, HeLa cells are tracked in M4 (PI negative, FITC Annexin V positive) and M2 
(PI positive, FITC Annexin V positive) which indicate early apoptotic and dead cells 
respectively. B. Representative quantitative analysis showing gradual increase of early 
apoptotic and dead cells with increasing exposure time to EA treatment. Results are 
presented as mean ± SE of n=3.  
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Figure 3.6.  Ellagic acid treatment induces caspase-mediated apoptosis. 
Immunoblot analysis of apoptosis executioner proteins, indicate the activation of 
caspase3 and caspase8 and the involvement of mitochondrial apoptotic pathway by the 
realease of cytochrome c into the cytosol.  
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Figure 3.7.  Apoptosis array analysis EA-treated HeLa cells. 
A. Apoptosis array profile of control and treated HeLa cells. Most significant differential 
expression was noticed in apoptosis inhibitors and receptors in control vs. treated 
proteome. B. Quantitative analysis was done using the average pixel density of duplicate 
protein spots compared to positive control. P-value calculated for surviving, XIAP DR4 
and DR5 pixel density < 0.05. 
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Figure 3.8. Tumor growth response to IT-EA treatment 
Ellagic acid inhibited the growth of HeLa xenografts via intratumoral administration. 
Data represent the mean of 6 tumors for control and 8 for treated group. Treatment was 
terminated on day 94. Tumor volume did not increase even after termination of treatment.  
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Figure 3.9. Tumor growth response to IP-EA treatment.  
Mice were treated with ellagic acid via IP injections. Control group received vehicle 
(Peg400). Control tumor volumes continued to grow while treated- tumor growth was 
repressed. Data points represent the mean of n=6 tumor measurements ± SEM. Treatment 
was terminated at day 94 and tumor growth was monitored until animal model ceased.  
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Figure 3.10.  Tumor sections H&E staining. 
A. control tumor section showing viable tumor cells with no sign of necrosis 
(vacuolization or cellular debris). B &C. intratumorally treated sections showing 
vacuolization and dead cells debris. 
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Figure 3.11.   H&E staining of organ sections from EA-treated xenografts 
HeLa xenografts organ sections showing no tissue toxicity or necrosis. 
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3.5 Discussion 
     Our data demonstrates that ellagic acid inhibits CK2 kinase activity in HeLa cells. 
Maximum inhibition occurred at 72h after ellagic acid treatment, and was followed by 
kinase activity rebound at 96 h. This could be a result of a decline in Ellagic acid 
inhibitory effect due to instability after 72 h. The increase in CK2 expression at 72 and 96 
h may be due to cells compensating for the loss of CK2 activity, which further explains 
the increase of CK2 acitivity at 96 h.  Results in this study suggest that EA interruption of 
CK2 signaling pathways is, at least in part, responsible for the inhibition of E6 and E7 
expression at the mRNA and protein levels. E6 and E7 abrogation of host defense 
mechanisms plays a key role in the development of cervical cancer. Inhibition of HPV 
oncogene expression restores tumor-suppressor protein levels and sensitizes cells to 
apoptosis. This series of events will likely cause a phenotype of tumor growth inhibition 
and apoptosis. However, the exact mechanism of CK2-mediated down regulation of E6 
and E7 remains to be elucidated. 
     E7 repression was associated with decreased expression of cyclin A. Given that S-
phase progression is controlled by CDK2/ cyclin A complex (18) and cyclin A 
transcription is controlled by E2F, cell accumulation in S-phase can be associated with 
E7 down regulation. The inhibitory effect of ellagic acid on E7 led to increased stability 
of pRb, and inhibited transcriptional activity of E2F therefore decreasing cyclin A 
expression. The latest event would induce S-phase arrest, which was observed in EA-
treated-HeLa cells. In addition, E6 inhibition stabilizes tumor suppressor protein p53 
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levels.  HeLa cells express wt-p53 at low levels. Raising p53 to normal levels may restore 
its normal activity as a pro-apoptotic protein. 
     Inhibition of CK2 kinase activity can induce multiple apoptotic pathways. Array 
analysis of HeLa apoptotic proteome showed an increase in the expression of death 
receptors most significantly was the increase in TRAIL R2/ DR5 receptor. DR5 
expression is regulated by p53 thus; it can be associated with stabilized p53 level. DR5 
bind death stimuli and cause activation of pro-caspase 8. Cross talk between the extrinsic 
(via death receptors) and the intrinsic (via the mitochondria) apoptotic pathways can 
occur through BID cleavage by caspase-8 and p53 upregulation of Bcl2 pro-apoptotic 
proteins expression (19). Inhibition of CK2 kinase activity renders BID susceptible to 
caspase-8 cleavage and restores p53 level. Therefore, either signal is capable of inducing 
the intrinsic pathway. This was indicated by the detection of mitochondrial release of pro-
apoptotic cytochrome c into the cytosol. The final outcome of extrinsic, intrinsic 
pathways is the activation of caspase 3, a terminal effector caspase that targets PARP for 
fragmentation (20, 21).  
     Most malignancies over-express IAP proteins to protect against death stimuli hence 
several anti-cancer therapeutics target IAP’s to induce cancer regression (22-24). IAPs 
including cIAP-1, cIAP-2, XIAP and survivin interfere with apoptosis pathways. Most 
potent apoptosis suppressor is XIAP that binds and inhibit activated caspase-3, caspse-7 
and caspase-9 (25). Controlling IAPs expression level is fundamental to sensitize cells to 
apoptosis (26). In this study, EA showed potent inhibition effect of IAP’s specifically 
XIAP and surviving which render cells susceptible to apoptosis signaling.   
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     Our in vivo evaluation of EA tumor-suppressive potential in mouse HeLa xenografts, 
via intratumoral and intra-peritoneal administration, showed high efficiency of EA in 
reducing HPV (+) cervical cancer tumor growth. EA treatment had no organ toxicity and 
resulted in relatively longer survival of tumor xenografts.  
     Overall evaluation of EA mechanism of action in HeLa cells indicates that EA, by 
targeting a multifunctional enzyme (CK2), inhibited HPV oncogene expression, and 
stabilizes tumor suppressor proteins p53 and pRb. EA inhibitory effect involves the 
activation of multiple pro-apoptotic proteins and the repression of anti apoptotic ones.  
Mechanism of action was mainly mediated by extrinsic apoptosis pathway and 
incorporated the intrinsic pathway as well. Multifunctional targets and activation of 
multiple apoptotic pathways is essential in cancer therapeutics to prevent drug resistance 
development in cancer. 
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CHAPTER IV 
HPV-NEGATIVE CERVICAL CARCINOMA:  
ELLAGIC ACID INHIBITS C33A CELLS GROWTH IN VITRO AND HAVE 
ANTI-TUMOR ACTIVITY IN VIVO.  
 
4.1 Abstract. 
     In this study, human cervical carcinoma cell line negative for human papillomavirus 
(HPV) DNA, was analyzed for its response to ellagic acid (EA) treatment. Cervical 
carcinoma cell line C33A, expressing mutated p53 and RB genes was highly sensitive to 
EA treatment. There was a marked inhibition of CK2 kinase activity with EA treatment. 
Apoptosis appeared to be the major mode of inhibition exerted on C33A cells by EA. 
Analysis of apoptosis inhibitors revealed a proportional relationship with cell toxicity. In 
vivo results showed that ellagic acid has potent anti-tumor activity in C33A xenografts.  
These results indicate that EA can bypass tumor suppressor proteins p53 and pRb 
function and induce cytotoxicity through inhibition of CK2 kinase activity. 
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4.2 Introduction: 
     Despite recent improvements in prevention, diagnosis and treatment, invasive cervical 
cancer remains a disease with high mortality rate in females in the United States and in 
developing countries (1, 2). High risk human papilloma virus (HR-HPV) was found to be 
the major etiologic factor of 90% of all cervical dysplasia diagnosed (3-7). The remaining 
10% can develop due to other unknown causes. However, there are factors that have been 
identified by the World Health Organization/ Information Center of Oncology 
(WHO/ICO) to be contributing to cervical cancer development. These include smoking, 
oral contraceptive use, fertility rate, sexual behavior and HIV prevalence.  
     Cellular homeostasis is defined as the process of balancing cell proliferation and cell 
death. Homeostasis is crucial to normal survival and development of normal tissue. It is 
regulated by multiple cellular proteins that form biological checkpoints to control cell 
growth and eliminate abnormally proliferating cells (8, 9). Cancer cells are usually 
defective in their ability to maintain normal cellular growth and to execute apoptosis 
when necessary. This could be a result of a genetic mutation, or an acquired oncogenic 
activity that interferes with normal cellular homeostasis machinery. In cervical cancer, 
the loss of p53 and pRb tumor suppressor activity is a common feature among HPV (+) 
and (-) cells, and fundamental to the development of malignant transformation of cervical 
epithelial tissue (10). As we mentioned in previous report the mechanism of malignant 
transformation of HPV-infected primary epithelial cells, have been related to HPV 
oncogenes E6- and E7- mediated inhibition of tumor suppressor proteins p53 and pRb 
respectively (3, 11-13). However, in HPV (-) C33A cell line abrogation of p53 and pRb 
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tumor suppressor activity is achieved by gene mutation. P53 gene mutation is mapped to 
core domain. A substitution of CGT→TGT at codon 273 results in amino acid change of 
Arg → Cys. Amino acids at core domain are required for direct contact with DNA (14). 
Thus this mutation causes accumulation of inactive p53 aggregates in C33A cells. On the 
other hand, a single G→A mutation in the intron/exon 20 splice junction of pRb-
encoding gene was found in C33A cells. This point mutation results in inactive protein 
that is defective in its ability to be phosphorylated (10). An effective anti-cancer drug is 
the one that can inhibit acquired oncogenic agents or bypass the genetic mutation effect, 
and render cancer cells responsive to death stimuli. 
     To complement our evaluation of the ellagic acid inhibition of HPV (-) cervical 
cancer, we decided to assess this beneficial effect through animal studies. Several in vivo 
assays have assessed the importance of ellagic acid in tumorogenesis inhibition. Ellagic 
acid chemopreventive activity against chemically induced cancers of skin, esophagus, 
lung and liver were demonstrated by animal studies. In 12-O-tetradecanoyl-phorbol-13-
acetate (TPA)-induced skin cancer mice models, ellagic acid topical application inhibited 
biochemical markers of skin cancer development including DNA synthesis, ornithine 
decarboxylase, and hydroperoxide production (15). Ellagic acid dietary supplement was 
proven to effectively inhibit N-nitrosomethyl- benzylamine (NMBA) - and 
methybenzylnitrosamine (MBN) - induced esophageal cancer (16-18). EA oral 
administration resulted in reversed fibrosis and significant reduction in elevated liver 
enzymes, lipid peroxidase and liver dihydroxy proline (19). In rat model of Crohn’s 
disease, (10-20 mg/kg) EA oral administration effectively diminished intestinal injuries, 
alleviated oxidative stress and restored pro-inflammatory proteins expression to normal 
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levels (20). It is well known that the gold standard assay in assessing a therapeutic 
potential of a compound is done through in vivo trials, thus, in vivo testing is 
fundamental to understanding tumor suppression activity of ellagic acid in cervical 
cancer xenografts.  
     We have demonstrated previously that ellagic acid (EA) induced anti-proliferative 
effect on broad spectrum of malignancies including HPV (+) HeLa and HPV (-) C33A 
cells. Our investigation of EA mechanism of action in HeLa cells revealed that CK2 
inhibition leads to abrogation of HPV oncogene expression. As a consequence p53 and 
pRb normal levels and function as tumor suppressors were rescued. pRb inhibited the 
expression of cyclin A, and p53 induced death receptor activation. Apoptotic pathway 
involved extrinsic and intrinsic routes and a concomitant inhibition of IAP’s that could be 
induced by CK2 inhibition. In this report, we are investigating CK2 inhibition 
downstream mechanism of action in the absence of HPV oncogenic activity and the 
irreversible loss of p53 and pRb normal activity.  
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4.3 Experimental Procedures:  
Cell culture. 
    C33A cells were cultured in RPMI (Cellgro), supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin (Cellgro). Cells were maintained in 5% CO2 at 37⁰ 
C. 
CK2 activity assay 
     CK2 activity in C33A cells was measured using whole cell lysates. Cells were 
extracted using ice-cold hypotonic buffer containing 20 mM Tris buffer, pH 8.0, 10% 
glycerol, 0.05% nonidet-P40, 2.0 mM EDTA, 2.0 mM EGTA and a cocktail of protease 
and phophatase inhibitors. Cell suspension was kept on ice for 30 minutes, and then spun 
down at 10,000 xg for 10 minutes at 4⁰ C. Endogenous kinase activity of CK2 was 
measured by CKII assay Kit (Upstate Biotechnology/ Millipore). 1 μg protein of cell 
lysates was added to a total volume of 40 μl containing assay dilution buffer (20mM 
MOPS, pH7.2, 25mM β-glycerol phosphate, 5mM EGTA, 1mM sodium orthovanadate, 
and 1mM dithiothretol), 0.4 mM of CK2-specific substrate peptide (R3D3SD3), inhibitor 
cocktail to block activity of other serine/threonine kinases in lysates, and diluted [γ-32P] 
ATP in MgCl2. The mixture was incubated at 30⁰C for 10 minutes, and then reaction was 
stopped by adding 20 μl of 40% trichloroacetic acid (TCA). Twenty-five microliter of 
reaction mixture was transferred to P81 paper discs and allowed to bind for 30 seconds. 
Paper discs were washed 3 times with 0.75% phosphoric acid for five minutes each and 
one time with acetone, allowed to dry before they were transferred to scintillation vials 
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with 2 ml of scintillation cocktail. Radioactivity of CK2 was counted using scintillation 
counter, expressed as c.p.m percentage of control radioactivity.  CK2 expression level 
was assessed by resolving 35 μg protein on 12% polyacrylamide-SDS gel, transferred to 
PVDF membrane and blotted with anti-CK2α antibody.  
Cell cycle analysis 
     C33A cells were plated at density of 1 x 10
5
cell/well and incubated for 24h with 50 
μM EA. The cells were then harvested and fixed in 90% ethanol at 4⁰ C. Cells were then 
washed with PBS and resuspended in a solution containing propidium iodide, sodium 
citrate, triton X and RNase, and incubated at 37⁰ C in the dark. After 30 min of 
incubation, samples were analyzed by Cytomics FC500 flow cytometer (Beckman 
Coulter), Quantitative cell cycle analysis was performed using CXP software. 
Trypan Blue Assay. 
     Trypan blue dye exclusion assay was done to test cytotoxicity of C33A to ellagic acid 
in time dependent manner. Cells were treated with 50 μM ellagic acid for 24, 48, 72 and 
96 h. At specified time points. Cells were collected and an aliquot of 500 μl was counted 
using Beckman Coulter Vi-Cell XR cell viability counter. Results were compared to 
control which was treated with the vehicle (Peg400) and collected after 96 h of 
incubation time.  
Annexin-V assay/ flow cytometry. 
     50 µM ellagic acid-treated cells were trypsinized and harvested at 24, 48, 72 and 96 h, 
washed once with cold PBS and resuspended in 100 µl Annexin-V binding buffer at 
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concentration of 1x10
3
 cells /μl. According to the manufacturer’s protocol, cells were 
then incubated with FITC-Annexin V and propidium iodide (PI) solution (FITC Annexin 
V Kit II, BD pharminogen) for 15 min at room temperature in the dark. Apoptosis 
induction was then analyzed on Cytomics FC500 flow cytometer (Beckman Coulter), 
using CXP software.  
Apoptosis array analysis.  
     C33 cells were plated in 100 mm dishes at a density of 1x 10
5
 cells/ml. Cells were 
treated with 0 or 50 μM ellagic acid and incubated at 37⁰ C for 96 h. After trypsinizing 
and harvesting of cells, they were rinsed with PBS and extracted at 1x10^7 cells/ml in kit 
lysis buffer (Human Apoptosis Array Kit; R&D Systems). The lysates were resuspended 
and rocked gently at 4⁰ C for 30 min. After centrifuging at 14,000 x g for 5 min, the 
supernatant was transferred into a clean tube. 400 µg protein was incubated with 
apoptosis array membrane according to manufacturer’s protocol. Apoptosis array data 
developed on X-ray film were quantified and analyzed using Image Quant TL v2005. 
Pixel density of protein spots were analyzed ad exported to excel. Average pixel density 
of 2 spots per protein was calculated. Negative control was used as background and 
subtracted from the mean. Results were then normalized to the positive control.   
Immunoblot. 
     C33A cells were treated with 50µM ellagic acid, and incubated for 24, 48, 72 and 96 
hours. Time point 0 was treated with the vehicle PEG400 only. Cells were harvested at 
indicated time points, washed with PBS and lysed in a buffer containing 150 mM sodium 
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chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate 
(SDS), and 50 mM Tris at pH 8.0 with a cocktail of protease inhibitors. Protein 
concentrations were determined using BCA protein assay (Biorad). An amount of 35 μg 
protein was taken from all samples and resolved on 12% polyacrylamide-SDS gel and 
transferred to PVDF membrane using semi dry transfer method. The membrane is then 
blocked with 5% milk and incubated with anti-PARP antibody (Cell Signaling).  
Ellagic acid effect on C33A xenograft.  
     Animal experiments were performed in accordance with guidelines approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Cleveland Clinic. Female 
athymic nu/nu mice were purchased from Case Comprehensive Cancer Center (CWRU). 
Cell inoculation was achieved by injecting mice subcutaneously with 1x10
6
 C33A cells 
suspended at 1x10
7
 cells/ml. Mice were randomized into two groups and were monitored 
daily until tumors reached approximately 100 mm
3
 in volume. Control groups received 
vehicle (Peg400) given intratumorally (IT) in a volume of 25 μl. Second group received 
ellagic acid treatment intratumoral at concentration 8 mg/kg and third group received 30 
mg/kg via intraperitoneal route. Treatments were given three times a week, tumor 
dimensions were measured using calipers and volume of tumor was calculated using the 
formula (Volume = 4/3 π a2b, where a=minor radius and b=major radius of the tumor).  
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Histology and immunohistochemistry.  
     Animal models were euthanized and tumors were harvested and fixed in 10% neutral 
buffered formalin. Sections of tumors were stained with hematoxylin and eosin (H&E). 
Slides were viewed microscopically.  
Statistical analysis 
     Data are expressed as mean ± SEM from at least 3 independent experiments.  
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4.4 Results 
The inhibitory effect of ellagic acid on CK2 activity in C33A cells. 
     A single administration of 50μM ellagic acid resulted in inhibition of endogenous 
CK2 phosphorylation of the CK2-specific peptide substrate (R3D3SD3 ). Maximum 
inhibition of CK2 activity occurred after 48 h of EA treatment (Fig. 4.1A). CK2 activity 
rebound effect was evident after 72 h. As we have mentioned in previous report, 72 h 
might be the maximal effective time for 50μM EA after which a second dose is required. 
Figure 4.1B shows an evaluation of CK2 expression and found that EA exerts its effect 
on catalytic activity of CK2 only and not on its expression level.  
Ellagic acid decreases viability and has no cell cycle effect in C33A. 
     Next, we assessed the effect of ellagic acid on cell cycle progression (Fig. 4.2). We 
previously showed that EA induced S-phase arrest in HeLa cells and we indicated the 
correlation between HPV oncogenic activity and cell cycle modulation in HeLa cells. As 
expected, HPV (-) C33A cells did not show any significant cell cycle modulation 
following EA treatment.  However, a single dose of 50μM ellagic acid reduced viability 
of C33A cells to < 60% after 48 h. After 96 h of ellagic acid treatment, viability was 
reduced to < 20% (Fig. 4.3). 
Ellagic acid Induces apoptosis in C33A cells. 
     Ellagic acid increased percent apoptotic cells (early+late) in a time-dependent manner. 
Apoptosis was detected by phosphatidylserine (PS) externalization. Exposed PS on the 
outer cellular membrane is an early sign of apoptosis induction and was tagged by FITC 
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annexin V staining. Positively stained cells shift rightward with increased time of EA 
treatment (Fig. 4.4A). Figure 4.4B illustrates quantitative analysis of the increased cell 
population in early and late stage apoptosis  
Apoptosis effector proteins are modulated by ellagic acid treatment. 
     To identify effector proteins involved in ellagic acid-induced apoptosis in C33A cells, 
we evaluated the difference in pro-apoptotic and anti-apoptotic proteins expression in 
untreated-C33A and treated-C33A cells. Figure 4.5 A, B, C show that ellagic acid does 
not exert a modulation on the expression of p53 and cyclin A. Fragmentation of PARP 
was evident at 48 h after ellagic acid treatment. Array analysis indicates that death 
receptor-mediated apoptosis pathway is not involved in the mechanism of C33A cell 
death. However, Ellagic acid stimulated the repression of apoptosis inhibitors family of 
proteins IAP’s including cIAP-1, cIAP-2, XIAP and Survivin (Fig. 4.6A, B). 
Impact of ellagic acid treatment on C33A xenografts. 
     Next, we wanted to investigate whether ellagic acid in vitro inhibitory effect can have 
therapeutic benefits in C33A animal models. Inhibition of CK2 kinase activity blocked 
tumor growth in C33A xenografts treated via intra-peritoneal and intra-tumoral routes 
with a more profound effect in IT-treated animal models (Fig. 4.7, 8). When HPV-
negative cervical cancer tumors reached a volume of 100 mm^3, the mice were randomly 
divided into 3 groups and treated as explained in the experimental methods section. 
Control tumors continued to grow progressively. Mice treated with intratumoral 
injections of EA exhibited  
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dramatic decrease in tumor growth. Mice treated with intaperitoneal injections showed 
decreased tumor volume compared to control mice. To assess the impact of CK2 
inhibition by EA in C33A tumors, control groups large tumors were injected with EA 
intratumorally. These tumors developed black, ulcerated lesions which upon examination 
by H&E staining was found to be necrotic tissue (Fig. 9).  
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Figure 4.1.  Ellagic acid inhibits CK2 kinase activity.  
A.CK2 phosphorylation assay of specific peptide was evaluated in the presence of 50μM 
ellagic acid at different time intervals. Data based on 3 independent studies, normalized 
to control (sample at time 0) and expressed as mean ± SEM. B. CK2 expression by 
immunoblot showing stable expression of CK2 protein.   
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Figure 4.2. Minimal change in cell cycle distribution in C33A cells.  
Ellagic acid-treated cells sorted by flow cytometry analysis of DNA content into G0/G1, 
S and G2/M phases, revealed no effect on cell cycle progression. Quantitative data 
represents mean of 3 independent assays ± SEM. 
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Figure 4.3.   Ellagic acid-induced CK2 inhibition decreases cell viability in vitro. 
Trypan blue cell viability assay of C33A cells treated with 50μM ellagic acid at different 
treatment exposure times. Data is based on 3 independent studies and expressed as mean 
± SEM.  
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Figure 4.4. Ellagic acid induces apoptosis in C33A cells in a time-dependent manner. 
A. Density blot showing increase of cells shift rightward with increased time of ellagic 
acid treatment, compared to control. Cells shifting to the right lower quadrant are positive 
for annexin V (early apoptosis) and cells shifting to right-upper quadrant are positive for 
annexin V + PI staining (late apoptosis). This shift is indicative of PS externalization as a 
measure of apoptosis induction. B. A quantitative histogram of 3 independent annexin V 
assays. Data represent mean of (early + late apoptotic cells) ± SEM. 
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Figure 4.5. Ellagic acid effect on p53, pRb and apoptosis terminal effector protein 
PARP. Immunoblot analysis of C33A cells showed elevated levels of p53 and pRb with 
no change in expression with ellagic acid treatment. PARP fragmentation illustrated at 48 
h of ellagic acid treatment is indicative of caspase-mediated apoptosis induction.  
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Figure 4.6.  Apoptosis array analysis idintifies apoptosis effector proteins involved 
in growth inhibition of C33A cells. A.TNF family of death receptors and IAP’s 
expression was evaluated in ellagic acid treated and untreated C33A samples. Each 
protein is represented by two duplicate expression dots on the array. B. Quantitative 
analysis was done by pixel density measurement normalized to positive control.  
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Figure 4.7. In vivo anti-tumor activity of intratumoral ellagic acid treatment. 
Data represent the average volume of 6 tumors treated via intratumoral injections three 
times a week ± SEM. Tumor volume decreased dramatically compared to Peg400 control 
group. Treated animals survived for 250 days.  
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Figure 4.8. In vivo anti-tumor activity of intraperitoneal ellagic acid treatment. 
Quantification of C33A tumor growth from inta-peritoneally injected ellagic acid 
compared to Peg400 treated control. Data presented as mean of 6 tumors in control and 
treated groups.  
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Figure 4.9. Development of necrosis in tumors following ellagic acid treatment. 
Control tumors were injected intratumorally with 8 mg/kg ellagic acid. Black necrotic 
tissue developed after 3 EA-treatments, which upon evaluating by H&E staining was 
found to be necrotic tissue.  
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4.5 Discussion 
     We investigated the anti-proliferative and anti-tumoral effects of EA in HPV (-) C33A 
cells and the mechanism of apoptosis induction in the absence of p53 and pRb tumor 
suppressor activity. Our in vitro results show that C33A cells were sensitive to 
micromolar doses of EA in time and dose dependent manner. EA induces CK2 kinase 
activity inhibition with no effect on CK2 expression in C33A cells. Tumor suppressor’s 
p53 and pRb are mutated in C33A cells thus; p53 and pRb expression was not affected by 
EA treatment. Ellagic acid mode of inhibition in C33A cells did not involve cell cycle 
arrest. However, flow cytometry analysis of PS early exposure as well as PARP 
fragmentation indicates caspase-mediated apoptosis induction. Decreased expression of 
XIAP, survivin, cIAP1 and cIAP2 is essential in the execution of apoptosis. IAPs are 
overexpressed in a variety of malignancies. They inhibit caspase activity and play a 
critical rule in chemotherapy resistance.  Repression of IAPs removes the block on 
caspase activity and renders cancer cells susceptible to apoptosis execution. In vivo study 
indicate EA is efficient in inhibiting HPV (-) cervical tumor growth by intratumoral and 
intraperitoneal treatment. 
     These results suggest that, ellagic acid-mediated CK2 inhibition is effective in 
inducing apoptosis in the absence of p53 and pRb tumor suppressor activity via IAP’s 
inhibition. Inhibiting a multifunctional target such as CK2, can bypass tumor suppressor 
gene mutation and induce cancer cell death.  
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CHAPTER V 
OVERALL CONCLUSION 
     It is now well known that HPV infection is a sexually transmitted disease that when 
persistent, can cause vaginal, penile, vulva, anal canal and head and neck cancers (1-4). 
The newly developed vaccine containing noninfectious peptide representing high risk 
(HR) HPV strains is effective at preventing HPV infections and subsequent dysplasia (4, 
5). Drug and Food Administration (FDA) has approved HPV vaccination for females 
aged 9-26. Recently females of any age are recommended to receive the vaccine as long 
as they test negative for HPV-DNA. This vaccine is a valuable tool in preventing HR-
HPV infection and cervical dysplasia (4, 6). However, implementation of HPV 
vaccination is very limited in developing countries where cervical cancer results in high 
mortality rate. The population who receive the vaccine is limited to females who are 
negative for HPV-DNA, while males are also at risk of developing HPV-mediated 
cancers (4). HPV vaccine protects against 70% of HPV strains but the duration of this 
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immunity is still uncertain. Women who receive the vaccine have to follow up with a 
yearly Papanicolaou (Pap-smear) to screen for the remaining 30% of HPV strains against 
which the vaccine does not provide immunity (4). The limitations of HPV vaccine leave a 
large population that remains at risk of developing HPV-related cancers.   
     Early detection of cervical cancer is necessary for optimal treatment outcome. Women 
have to undergo a yearly Papanicolaou for early detection of cervical dysplasia. Currently 
the standard care for abnormal cytology, which is determined by pap-smear screening, is 
immediate colposcopy and biopsy of all suspected lesions. Biopsy specimen analysis 
determines the histologic diagnosis. Both cytology and histology analysis can then 
determine the degree of cervical dysplasia according to the Bethesda System (7). This 
categorization system divides abnormal cytology into two main groups: squamous and 
glandular origins. Squamous cell origins include atypical squamous cells, low-grade 
squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion 
(HSIL) and squamous cell carcinoma. Glandular cell origins include: atypical cells, 
atypical favoring neoplasia, endocervical adenocarcinoma in situ, adenocarcinoma (7). 
Cytology diagnosis is further confirmed by histology diagnosis, which is categorized into 
Low-grade cervical intraepithelial neoplasia (CIN1) which falls under LSIL; and 
Moderate and severe CIN2 and CIN3 (CIN3 indicates carcinoma in situ) which fall under 
HSIL (7, 8). Once cervical carcinoma is confirmed by cytology and histology 
examination, a clinical staging has to be determined according to International Federation 
of Gynecology and Obstetrics (FIGO). Depending on clinical staging of cervical 
neoplasia, treatment can be determined (8). 
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Figure 5.2. Cervical dysplasia classification according to cytology and histology 
analysis. From Lowy & Schiller, J Clin Invest, 116:1167-73, 2006 
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     Cervical cancer treatment is aggressive and can include; radiation (external beam 
radiation or intra-vaginal), chemotherapy (cisplatin (CDDP) and 5-fluorouracil (5-FU)), 
surgery which may involve  radical hysterectomy and pelvic lymphadenectomy (8). In 
most cervical cancer cases combined therapy is necessary. Combined radical surgery and 
radiation is used to treat certain stages of cervical cancer, however, this therapy is 
associated with toxic side effects (8). Combined chemo-radiotherapy is considered the 
gold standard treatment for cervical carcinoma. Although, the later therapy improves 
survival rate in cervical cancer patients, it can cause severe acute and late toxic effects (9, 
10). Acute toxicity of concurrent chemotherapy and radiotherapy treatment manifest in 
hematologic and gastrointestinal complications that may require hospitalization (10). Late 
toxicity can include small bowel obstruction, ureteric fibrosis, pulmonary embolus, sepsis 
and toxic death (9).  
     The aggressiveness of these therapies and the development of chemo- and radio- 
therapy resistant tumor cells increased the need for an improved anti-cervical cancer drug 
(11). We found that ellagic acid-mediated CK2 inhibition has antiproliferative and 
apoptotic activity against cervical carcinoma in vitro and in vivo. Ellagic acid appears to 
present an anti-viral effective strategy that is safe, multifunctional (to avoid cancer cells 
resistance development), and has the ability to bypass tumor suppressors’ mutation to 
induce cancer cell death.  
     Comparing HPV (-) C33A and HPV (+) HeLa cervical cancer cells in their response 
to ellagic acid- mediated CK2 inhibition, we found that C33A showed greater sensitivity 
in time- and dose- dependent manner compared to HeLa cells. We hypothesized that this 
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difference was due to differential gene expression. Therefore, we analysed major 
oncogene expression differences via immunobloting (Fig. 2). Immunoblot analysis in 
HeLa cells confirm the expression of HPV18-E6 and -E7, show normal level of cyclin A 
as a product of pRb-E2F transcription activity, and undetectable p53. C33A on the other 
hand, is negative for HPV-E6 and E7 expression, expresses elevated level of mutated p53 
and normal expression level of cyclin A. When we compared CK2 expression, we found 
that it is expressed at elevated level in C33A cells compared to HeLa. This suggests that 
HeLa might be more sensitive to ellagic acid inhibitory effect compared to C33A. 
However, as indicated in our previous reports, C33A is more sensitive than HeLa. This 
suggests that HPV-oncogenic activity delays HeLa response to CK2 inhibition and 
hinders it from being as sensitive to ellagic acid treatment as C33A.  
     Comparing ellagic acid mechanism of action in HeLa and C33A cells will provide 
insight into the molecular mechanism of action of ellagic acid in different proteome 
profiles. This comparison study revealed apoptosis as the common inhibitory mechanism 
in both C33A and HeLa cells in time- and dose- dependent manner. Cell cycle arrest was 
partly involved in ellagic acid inhibitory effect in HeLa cells. This specificity to HeLa 
cells is associated with the oncogenic activity of HPV-E7 as the later plays an important 
role in regulating cell cycle machinery. We predicted major differences in the underlying 
mechanism of apoptosis induction in HeLa and C33A cells. This was confirmed by 
different expression of effector proteins involved in apoptosis induction in HeLa and 
C33A cells. HeLa showed a combination of TRAIL death receptor activation, 
mitochondrial involvement, and IAP’s inhibition. In contrast, C33A cells showed IAP’s  
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Figure 5.3. Immunoblot comparison analysis of gene differential expression in HeLa 
and C33A cells.  
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as the major effector proteins involved in apoptosis induction.  
     In vivo study of ellagic acid effect on HeLa and C33 tumors was consistent with 
previous in vitro results. At low dose application of ellagic acid, HeLa exhibited less 
sensitivity to intratumoral treatments than C33. However, at higher dose, HeLa and C33 
tumors demonstrated similar response to intra-peritoneal administration of ellagic acid. It 
is noteworthy that upon treating HeLa and C33 tumors in control groups with ellagic 
acid, both tumors developed areas of necrosis. This further confirms ellagic acid 
effectiveness in tumor growth inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
5.2 REFERENCE LIST 
 
1. Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, et 
al. High-risk human papillomavirus is sexually transmitted: Evidence from a 
follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol 
Biomarkers Prev 2001;10:101-6. 
 
2. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human 
papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003:14-9. 
 
3. Syrjänen S. Human papillomaviruses in head and neck carcinomas. N Engl J Med 
2007;356:1993-5. 
 
4. Hakim AA, Lin PS, Wilczynski S, Nguyen K, Lynes B, Wakabayashi MT. 
Indications and efficacy of the human papillomavirus vaccine. Curr Treat Options 
Oncol 2007;8:393-401. 
 
5. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 
2006;116:1167-73. 
 
6. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. 
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial 
neoplasia: A randomized controlled trial. Obstet Gynecol 2006;107:18-27. 
106 
 
 
7. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 
2001 bethesda system: Terminology for reporting results of cervical cytology. 
JAMA 2002;287:2114-9. 
 
8. Long HJ, Laack NN, Gostout BS. Prevention, diagnosis, and treatment of cervical 
cancer. Mayo Clin Proc 2007;82:1566-74. 
 
9. Spensley S, Hunter RD, Livsey JE, Swindell R, Davidson SE. Clinical outcome 
for chemoradiotherapy in carcinoma of the cervix. Clin Oncol (R Coll Radiol) 
2009;21:49-55. 
 
10. Eifel PJ. Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat 
Oncol 2006;16:177-85. 
 
11. Saxena A, Yashar C, Taylor DD, Gercel-Taylor C. Cellular response to 
chemotherapy and radiation in cervical cancer. Am J Obstet Gynecol 
2005;192:1399-403. 
 
 
 
